2025-10-19 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the provided data, formatted for readability and including key metrics.

## TMDX (TransMedics Group Inc.) Analysis

TransMedics Group Inc. is a medical technology company focused on preserving organs for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 194.63%
*   **VOO Cumulative Return:** 72.29%
*   **Absolute Spread:** 106.9 (TMDX outperformed VOO)
*   **Relative Spread:** 56.4 (Position within historical spread range)

**Analysis:** TMDX has significantly outperformed the S&P 500. The Relative Spread of 56.4 indicates that while the outperformance is substantial, it's positioned somewhat mid-range within its historical deviation from the S&P 500.

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0%  | -0.0   | 0.7    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%   | 0.0    | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%   | 0.1    | 2.7    |
| 2022-2024  | 130.0%  | 85.5% | 109.0%  | 0.1    | 2.1    |
| 2023-2025  | 115.0%  | 85.5% | 54.0%   | 0.3    | 4.0    |

**Analysis:**

*   **CAGR:**  Shows strong growth in recent periods (2020-2025), but volatile returns.
*   **MDD:**  High Maximum Drawdown suggests significant price volatility.
*   **Alpha:** Consistently positive Alpha indicates outperformance relative to the market risk-free rate.
*   **Beta:** Low Beta values suggest TMDX's price is not highly correlated with the overall market.
*   **Cap(B):** Shows that TMDX is getting bigger and bigger.

### 2. Recent Stock Price Movements

*   **Current Price:** 117.63
*   **Previous Close:** 115.68
*   **Change:** 1.69
*   **5-day Moving Average:** 113.77
*   **20-day Moving Average:** 114.52
*   **60-day Moving Average:** 116.15

**Analysis:** The price is above all three moving averages, suggesting an upward trend. The positive change from the previous close confirms recent positive momentum.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment Risk)
*   **RSI:** 57.55 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.2694 (Positive - indicates upward momentum)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90)
*   **Delta_Previous_Relative_Divergence:** -2.4 (Indicates short-term downward movement)
*   **Expected Return:** 57.3% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests low investment risk. RSI is neutral. PPO indicates upward momentum.  The "Hybrid Signal" suggests a strong buy recommendation based on a composite of factors. The negative Delta_Previous_Relative_Divergence suggests caution regarding short-term pullbacks. The high Expected Return indicates significant potential for long-term outperformance if investing from now. The significant positive price change reinforces recent positive momentum.

### 4. Recent News & Significant Events

*   **October 15, 2025:**  TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025.
*   **October 14, 2025:** TransMedics Group Stock Earns Relative Strength Rating Upgrade.
*   **October 13, 2025:** Jefferies Initiates TransMedics Group at Buy With $145 Price Target.
*   **October 9, 2025:**  Growth in Returns On Capital.
*   **October 8, 2025:** Highlighted as an Outstanding Healthcare Stock to Buy and Hold for a Decade.
*   **September 24, 2025:** Identified as a Strong Growth Stock.

**Analysis:** Recent news is overwhelmingly positive, with analyst upgrades, recognition as a growth stock, and positive outlooks on capital returns. Jefferies' $145 price target suggests further upside.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (~1.75)
*   **Target Price:** 141.00 (Average) / 170.00 (High) / 114.00 (Low)

**Analysis:** Analyst sentiment is bullish, with a "Buy" consensus and an average price target significantly above the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has consistently exceeded EPS expectations in recent quarters. This suggests strong financial performance and effective management.

### 6. Financial Information

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.16B    | 61.38%        |
| 2025-03-31 | $0.14B    | 61.47%        |
| 2024-12-31 | $0.12B    | 59.21%        |
| 2024-09-30 | $0.11B    | 55.94%        |
| 2024-06-30 | $0.11B    | 60.59%        |

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $0.32B    | 10.97%  |
| 2025-03-31 | $0.27B    | 9.64%   |
| 2024-12-31 | $0.23B    | 3.00%   |
| 2024-09-30 | $0.21B    | 2.01%   |
| 2024-06-30 | $0.19B    | 6.42%   |

**Analysis:** Revenue is consistently growing. Profit margins are strong and relatively stable. ROE has shown significant improvement, indicating increasing profitability relative to equity.

### 7. Overall Summary

TransMedics Group Inc. (TMDX) exhibits strong growth potential and positive momentum. It has significantly outperformed the S&P 500, with recent financial performance exceeding expectations. Analyst sentiment is bullish, and recent news reinforces a positive outlook.  While the stock has historically exhibited volatility (high MDD), current indicators suggest a favorable investment opportunity, particularly for long-term investors. However, the short-term divergence metric suggests being mindful of potential pullbacks. The high expected return makes it attractive for long-term investment.
